Targeting MED23 inhibits hepatocellular carcinoma development by suppressing compensatory proliferation and...

Area of Science:

• Hepatocellular carcinoma (HCC) research
• Molecular mechanisms of liver cancer
• Mediator complex function

Background:

• Hepatocellular carcinoma (HCC) is linked to proliferating hepatocytes in damaged livers.
• The Mediator complex regulates transcription factors and cofactors in physiological and pathological processes.
• Molecular mechanisms driving HCC progression remain largely unknown.

Purpose of the Study:

• To investigate the role of Mediator subunit MED23 in hepatocellular carcinoma (HCC) development.
• To elucidate the molecular mechanisms by which MED23 influences HCC progression.
• To identify potential therapeutic strategies for HCC targeting the MED23 pathway.

Main Methods:

• Utilized diethylnitrosamine (DEN)-induced HCC mouse models.
• Performed liver-specific ablation of Med23 (constitutive and inducible).
• Assessed hepatocyte viability, NQO1 protein stability, reactive oxygen species (ROS) production, and IGF2 expression.

Main Results:

• Liver-specific ablation of Med23 significantly inhibited HCC development in mouse models.
• MED23 deficiency reduced hepatocyte viability by decreasing NQO1 stability and increasing ROS.
• MED23 collaborates with RFX5 to regulate IGF2 enhancer function, impacting hepatocyte viability and HCC.
• IGF2 overexpression in MED23-deficient cells partially restored cell growth and reduced apoptosis.

Conclusions:

• The MED23-IGF2-NQO1 axis is significant in HCC progression.
• MED23 plays a critical role in maintaining hepatocyte viability and driving HCC.
• Targeting the MED23-IGF2-NQO1 pathway presents a novel therapeutic strategy for HCC.